251 publications
Explanation of the Interest Form - MEB-ZIN Parallel Procedures pilot
Accelerating patient access to reimbursable innovative medicines has been on the wish list of the government, patient ...
Erenumab (Aimovig®) for the prophylaxis of adults with migraine
Zorginstituut Nederland has completed its assessment whether erenumab (Aimovig®) for the prophylaxis of adults with migraine, can ...
Ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma
Zorginstituut Nederland has completed its assessment whether ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line treatment ...
Venetoclax (Venclyxto®) in combination with rituximab for the treatment of chronic lymphocytic leukaemia (CLL)
Zorginstituut Nederland has completed its assessment whether venetoclax (Venclyxto®) in combination with rituximab for the ...
Tezacaftor/ivacaftor (Symkevi®) with ivacaftor monopreparation (Kalydeco®) for the treatment of cystic fibrosis
Zorginstituut Nederland carried out an assessment in relation to extending the specific conditions for the medicinal product ...
Assessment of 'established medical science and medical practice’ - a technical modification
This report is a supplement to the existing Dutch assessment framework dating form 2015. It can be used to investigate whether an ...
Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults
Zorginstituut Nederland carried out a marginal assessment whether the product brexpiprazole (Rxulti®) can be accepted into the ...
Pitolisant (Wakix®) for the treatment of narcolepsy in adults
Zorginstituut Nederland carried out a marginal assessment whether pitolisant (Wakix®) is interchangeable with a drug currently ...
Glycopyrronium bromide (Sialanar®) for the symptomatic treatment of severe sialorrhoea
Zorginstituut Nederland carried out an assessment whether the product glycopyrronium bromide (Sialanar®) is interchangeable with ...
Tolvaptan (Jinarc ®) for the treatment of chronic kidney disease - alteration of the specific conditions
Zorginstituut Nederland carried out an assessment whether the specific conditions for tolvaptan (Jinarc ®) can be altered. ...